Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer

American Journal of Clinical Pathology

Volumn 129, Issue 5, 2008, Pages 756-762

  Altimari, Annalisa ^a   Grigioni, Antonia D'Errico ^a,d   Benedettini, Elisa ^a   Gabusi, Elena ^a   Schiavina, Riccardo ^b   Martinelli, Antonio ^b   Morselli Labate, Antonio Maria ^c   Martorana, Giuseppe ^b   Grigioni, Walter Franco ^a   Fiorentino, Michelangelo ^a  

^a F Addarii Institute of Oncology   (Italy)

^b Department of Urology ^*  (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Istituto Oncologico Addarii   (Italy)

Author keywords

Blood tumor markers; DNA methylation; Free plasma DNA; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; DNA; FREE PLASMA DNA; PROSTATE SPECIFIC ANTIGEN; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; GENETICS; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROC CURVE;

AGED; AREA UNDER CURVE; DNA METHYLATION; DNA, NEOPLASM; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 44849097875     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/DBPX1MFNDDJBW1FL     Document Type: Article

References (29)

1. Jemal A, Tiwani RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. La Vecchia C, Bruzzi P, Decarli A, et al. An estimate of prostate cancer prevalence in Italy. Tumori. 2002;88:367-369.
3. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet. 2003;361:1122-1128.
4. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97:1132-1137.
5. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res. 2004;10:3943-3953.
6. Sidransky D. Circulating DNA: what we know and what we need to learn. Ann N Y Acad Sci. 2000;906:1-4.
7. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000;906:161-168.
8. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95:114-120.
9. Taback B, Hoon DSB. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci. 2004;1022:1-8.
10. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003;21:3902-3908.
11. Holdenrieder S, Stieber P. Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci. 2004;1022:211-216.
12. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981-5987.
13. Allen D, Butt A, Cahill D, et al. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci. 2004;1022:76-80.
14. Papadopoulou E, Davilas E, Sotiriou V, et al. Cell-free DNA in plasma as a new molecular marker for prostate cancer. Oncol Res. 2004;14:439-445.
15. Boddy JL, Gal S, Malone PR, et al. Prospective study on quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate diseases. Clin Cancer Res. 2005;11:1394-1399.
16. Chun FK, Muller I, Lange I, et al. Circulating tumor-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 2006;98:544-548.
17. Schwarzenbach H, Chun FK, Lange I, et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer. 2007;120:1465-1471.
18. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004;10:8472-8478.
19. Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol. 2004;46:660-669.
20. Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst. 2003;95:1634-1637.
21. Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000;60:5941-5945.
22. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci. 2001;945:51-58.
23. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 methylation in bodily fluids of patients with prostate cancer. Urology. 2002;60:1131-1135.
24. Greene FL, Page DL, Fleming ID, et al; for the American Joint Committee on Cancer, eds. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
25. Gleason DF. Classification of prostatic carcinoma. Cancer Chemother Rep. 1966;50:125-128.
26. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577.
27. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
28. Pezzilli R, Morselli-Labate AM, Miniero R, et al. Simultaneous serum assays of lipase and interleukin-6 for early diagnosis and prognosis of acute pancreatitis. Clin Chem. 1999;45:1762-1767.
29. Schambart DH, Maiazza R, Kurth KH. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology. Int J Oncol. 2005;26:565-577.